Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2024-12-03 00:00:00 ET · period of report 2024-12-01 · accession 0001415889-24-028070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-03 | 2024-12-01 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | +21.6K | 48.6K | +80% | $0 |
| D | 2024-12-03 | 2024-12-01 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | -21.6K | 4,317 | -83% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-01 | M | A | 21,591 | $0.00 | 48,591 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit (RSU) | 2024-12-01 | M | D | 21,591 | $0.00 | 4,317 | D | — · — to 2025-12-01 | 21,591 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. (F2) 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. |